Literature DB >> 34414638

Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication.

Xingyu Yao1,2, Shiyu Xiao1,2, Liya Zhou1,2.   

Abstract

BACKGROUND: Bismuth-based drugs are used to treat Helicobacter pylori infection; however, the antibacterial activity of bismuth, especially against H. pylori, has not been fully elucidated. In this study, the mechanisms by which bismuth exerts its detrimental effects on H. pylori were evaluated. Methods Six H. pylori strains isolated from different patients were cultured with or without bismuth; proteins and metabolites differentially expressed in these two sets of bacteria were detected via data independent acquisition proteomic and gas chromatography-mass spectrometry metabolic approaches, respectively. Gene ontology functional analysis and Kyoto Encyclopedia of Genes and Genomes database were used to identity pathway enrichment.
RESULTS: Bismuth inhibited H. pylori growth in vitro via the following mechanisms: downregulation of virulence proteins CagA and VacA; disruption of flagella assembly responsible for bacterial colonization; and inhibition of antioxidant enzymes, including catalase, catalase-related peroxidase, and superoxide dismutase. Diverse metabolic pathways related to growth and RNA translation in H. pylori were disrupted by bismuth. Bismuth treatment impaired many biological processes in H. pylori, including antioxidant response and purine, pyrimidine, amino acid, and carbon metabolism. Conclusions The findings of this study suggest that motility, virulence factors CagA and VacA, antioxidant defense system, and many important metabolic pathways associated with bacterial growth, including nucleotide and amino acid metabolism and translation in H. pylori, are inhibited by bismuth. This study provides novel insights into the mechanism by which bismuth eradicates H. pylori upon being incorporated into quadruple therapy.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Helicobacter pylorizzm321990; antibacterial mechanism; bismuth; metabolomics; proteomics

Mesh:

Substances:

Year:  2021        PMID: 34414638     DOI: 10.1111/hel.12846

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  2 in total

1.  Metagenomic Changes of Gut Microbiota following Treatment of Helicobacter pylori Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or Lactobacillus reuteri.

Authors:  Maria Pina Dore; Rosangela Sau; Caterina Niolu; Marcello Abbondio; Alessandro Tanca; Stefano Bibbò; Mariafrancesca Loria; Giovanni Mario Pes; Sergio Uzzau
Journal:  Nutrients       Date:  2022-07-06       Impact factor: 6.706

2.  Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy.

Authors:  Giuseppe Losurdo; Ilaria Lacavalla; Francesco Russo; Giuseppe Riezzo; Irene Vita Brescia; Maria Rendina; Enzo Ierardi; Alfredo Di Leo
Journal:  Antibiotics (Basel)       Date:  2022-01-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.